Adenoviral Vector with KRAS-Responsive Promoter for Tumor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, including surgery, chemotherapy, and radiation, often fail to effectively target and eliminate cancer cells, particularly those with activating RAS mutations and p53 dysfunction, leading to resistance and recurrence.
Innovation Solution
A conditionally-replicative adenoviral vector is developed, utilizing a Δp53REP2 promoter that is responsive to activating KRAS mutations but not p53 status, incorporating Hdm2-encoding DNA and E1A/E1B-19 kD genes, to selectively replicate and lyse tumor cells while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies (surgery, chemotherapy, radiation) are used, then treatment can be administered to patients, but they fail to effectively target and eliminate cancer cells with activating RAS mutations and p53 dysfunction, leading to resistance and recurrence
Solution Approach 1:
The patent creates a viral vector with localized specificity by using a promoter that responds only to activating RAS mutations, not to all cancer-related genetic alterations. This allows the therapy to be highly effective against RAS-mutant cancers while sparing normal cells and other cancer types, resolving the contradiction between reliability for a specific target and adaptability across diverse cancers.
Solution Approach 2:
The invention changes the activation parameter from general cancer markers to a specific molecular signature (activating RAS mutations). By using a promoter responsive specifically to RAS mutation status rather than general cancer presence, the therapy achieves high reliability for its target population while the parameter change itself defines the selective adaptability to RAS-mutant cancers.
2Reliability
If a viral vector is designed to replicate in all tumor cells, then broad anti-cancer activity is achieved, but normal cells with p53 wild-type are also affected causing toxicity
Solution Approach 1:
The viral vector is engineered with a promoter that confers local specificity to RAS-mutant cells. The promoter responds only to the molecular signature of activating RAS mutations, creating a quality difference between how the vector behaves in RAS-mutant tumor cells versus normal cells with p53 wild-type, thereby achieving anti-tumor activity without normal cell toxicity.
Solution Approach 2:
The promoter acts as an intermediary element that mediates between the viral replication machinery and the host cell's RAS mutation status. It translates the molecular signature of RAS mutations into selective viral replication activation, allowing the virus to distinguish between tumor and normal cells based on RAS mutation presence rather than directly sensing p53 status.
3Reliability
If E1B-55 kD-deleted adenoviruses are used to target p53-nonfunctional tumors, then selective cytopathic effect is achieved, but they fail to replicate efficiently in cells with p53 wild-type and cannot target tumors with activating RAS mutations
Solution Approach 1:
The patent fundamentally changes the selection parameter from p53 functionality to RAS mutation status. By using a promoter responsive to RAS mutations rather than relying on p53 deletion status, the viral vector can target tumors with activating RAS mutations regardless of their p53 status, thereby expanding adaptability to different molecular subtypes while maintaining selective cytopathic effect through the conditional replication mechanism.
Solution Approach 2:
Instead of deleting viral genes to target p53-nonfunctional tumors (the conventional approach), the patent inverts the strategy by using a promoter that detects the presence of activating RAS mutations. This inversion allows targeting of a different molecular subtype (RAS-mutant cancers) while achieving similar selective replication and cytopathic effects through the opposite molecular mechanism.
Data Source
AI summary
The invention constructs an activating KRASmutant but not p53-responsive promoter and generates an E1B-55kD-deleted (ΔE1B-55kD) adenovirus, harboring a transcriptionally activating transgene and holding lytic replication ability in the tumor cells with activating KRASmutant. The adenovirus of the invention can be used in the treatment of cancers.